Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) - The Eastern Cooperative Oncology Group (ECOG) Results

Avi I. Einzig; Stuart Lipsitz; Peter H. Wiernik; Al B. Benson

doi:10.1007/BF00873804

Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) - The Eastern Cooperative Oncology Group (ECOG) Results

Avi I. Einzig^*, Stuart Lipsitz, Peter H. Wiernik, Al B. Benson

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Taxol was administered as a 24-hour continuous infusion at 250 mg/m² in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered between July 1991 and June 1992, twenty-three were eligible and were evaluated for toxicity and twenty-two were assessable for response. There was one partial response (4.5%) in a patient with liver metastases, with a duration of 6 months. Toxicity was primarily neutropenia. Taxol as a single agent appears to have little activity in adenocarcinoma of the UGIT.

Original language	English (US)
Pages (from-to)	223-227
Number of pages	5
Journal	Investigational New Drugs
Volume	13
Issue number	3
DOIs	https://doi.org/10.1007/BF00873804
State	Published - Sep 1995

Keywords

Taxol (paclitaxel)
upper gastrointestinal tumors

ASJC Scopus subject areas

Pharmacology (medical)
Oncology
Pharmacology

Access to Document

10.1007/BF00873804

Cite this

@article{cd880a75782d49c0b227b10da635d00a,

title = "Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) - The Eastern Cooperative Oncology Group (ECOG) Results",

abstract = "Taxol was administered as a 24-hour continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered between July 1991 and June 1992, twenty-three were eligible and were evaluated for toxicity and twenty-two were assessable for response. There was one partial response (4.5%) in a patient with liver metastases, with a duration of 6 months. Toxicity was primarily neutropenia. Taxol as a single agent appears to have little activity in adenocarcinoma of the UGIT.",

keywords = "Taxol (paclitaxel), upper gastrointestinal tumors",

author = "Einzig, {Avi I.} and Stuart Lipsitz and Wiernik, {Peter H.} and Benson, {Al B.}",

year = "1995",

month = sep,

doi = "10.1007/BF00873804",

language = "English (US)",

volume = "13",

pages = "223--227",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) - The Eastern Cooperative Oncology Group (ECOG) Results

AU - Einzig, Avi I.

AU - Lipsitz, Stuart

AU - Wiernik, Peter H.

AU - Benson, Al B.

PY - 1995/9

Y1 - 1995/9

N2 - Taxol was administered as a 24-hour continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered between July 1991 and June 1992, twenty-three were eligible and were evaluated for toxicity and twenty-two were assessable for response. There was one partial response (4.5%) in a patient with liver metastases, with a duration of 6 months. Toxicity was primarily neutropenia. Taxol as a single agent appears to have little activity in adenocarcinoma of the UGIT.

AB - Taxol was administered as a 24-hour continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered between July 1991 and June 1992, twenty-three were eligible and were evaluated for toxicity and twenty-two were assessable for response. There was one partial response (4.5%) in a patient with liver metastases, with a duration of 6 months. Toxicity was primarily neutropenia. Taxol as a single agent appears to have little activity in adenocarcinoma of the UGIT.

KW - Taxol (paclitaxel)

KW - upper gastrointestinal tumors

UR - http://www.scopus.com/inward/record.url?scp=0029550022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029550022&partnerID=8YFLogxK

U2 - 10.1007/BF00873804

DO - 10.1007/BF00873804

M3 - Article

C2 - 8729950

AN - SCOPUS:0029550022

SN - 0167-6997

VL - 13

SP - 223

EP - 227

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) - The Eastern Cooperative Oncology Group (ECOG) Results

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this